BeOne Medicines (BEIGF) Total Liabilities (2015 - 2026)

BeOne Medicines (BEIGF) has reported Total Liabilities for 12 consecutive years, with $4.0 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Liabilities rose 58.3% year-over-year to $4.0 billion in Q2 2026; TTM through Jun 2026 was $4.0 billion, a 58.3% increase from a year earlier, with the FY2025 full-year figure at $3.8 billion, up 47.85% from the prior year.
• Total Liabilities was $4.0 billion for Q2 2026 at BeOne Medicines, up from $3.8 billion in the prior quarter.
• Over five years, Total Liabilities peaked at $4.0 billion in Q2 2026 and troughed at $1.8 billion in Q3 2023.
• A 5-year average of $2.5 billion and a median of $2.3 billion in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities slipped 16.94% in 2022 and soared 61.96% in 2026, its largest moves.
• Over 5 years, Total Liabilities stood at $2.0 billion in 2022, then gained by 13.63% to $2.3 billion in 2023, then grew by 14.14% to $2.6 billion in 2024, then jumped by 47.85% to $3.8 billion in 2025, then climbed by 4.55% to $4.0 billion in 2026.
• The last three Total Liabilities figures came in at $4.0 billion (Q2 2026), $3.8 billion (Q1 2026), and $3.8 billion (Q4 2025), per Business Quant data.